Evidence map›Paper›PMID 39948217›Full record

SynthesisEuropean journal of clinical pharmacology2025

Evaluating the safety and efficacy of nirmatrelvir-ritonavir therapy in pregnant women with COVID-19: a systematic review and meta-analysis.

Omar Hassan, Aya Abdulkarim Elbhairy, Aya Magdy Siam, Tasneem Abdelwahab, Albraa Ashraf Hamad, Omar Ehab Mahmoud, Omnia Azmy Nabeh

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in European journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Omar HassanMedical Research Group of Egypt, Negida Academy, Arlington, MA, USA.ORCID http://orcid.org/0009-0007-3566-4076
Aya Abdulkarim ElbhairyKasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0009-0001-6318-2855
Aya Magdy SiamKasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0009-0002-8616-6644
Tasneem AbdelwahabKasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0009-0002-3176-6909
Albraa Ashraf HamadKasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0009-0000-5444-1424
Omar Ehab MahmoudKasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0009-0003-7180-5260
Omnia Azmy NabehKasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt. omnia.azmy@kasralainy.edu.eg.ORCID http://orcid.org/0000-0001-7959-9316

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePregnant women are at heightened risk for severe COVID-19 outcomes. However, treatment options during pregnancy remain limited due to concerns over their safety and efficacy.

methodsThis systematic review and meta-analysis assessed the safety and efficacy of nirmatrelvir-ritonavir in pregnant women diagnosed with mild-to-moderate COVID-19. The analysis focused on cases where the treatment was initiated within five days of symptom onset. A single-arm meta-analysis was performed to comprehensively evaluate outcomes across maternal, delivery, and neonatal domains.

resultsIn line with PRISMA guidelines, six studies involving a total of 427 pregnant patients were included in the analysis. Hospitalization was reported in 2% of patients (95% CI: 1%-5%), with low heterogeneity across studies (I

conclusionNirmatrelvir-ritonavir appears safe and effective for mild-to-moderate COVID-19 in pregnant women, with low rates of hospitalization and adverse maternal outcomes. Larger, randomized studies are crucial to confirm these findings and ensure safety in diverse populations.

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentPregnancy Complications, InfectiousRitonavirCOVID-19Drug CombinationsFemaleHospitalizationHumansPregnancyPregnancy OutcomeSARS-CoV-2Treatment OutcomeAntiviral AgentsDrug CombinationsRitonavirCOVID-19FetalNeonatesNirmatrelvir-RitonavirPregnancySARS-COV2

Identifiers

PMID39948217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.